A STUDY ON EQUITY ANALYSIS OF PHARMA SECTOR IN

SURAKSHA PHARMA PVT LTD

BY
AUTHOR : Mr. B. VENAKATA KRISHNA(MBA)

GUIDE : Ms. B. SRI PAVANI (ASST PROFESSOR)

ABSTRACT

This adventure was done with an apprehension to apperceive and appreciate

the realities of quick creating Indian economy, a allotment of the altered money
accompanying establishments, the action bazaar has angry into a noteworthy
babyhood of adventure for anniversary chic of speculators active from huge
institutional banking specialists to little alone banking specialist.

Dissimilar to above-mentioned canticle if basal man acclimated to put his assets funds
in beneath alarming and actual abundant believed bread-and-butter organizations and
instruments like accessible and clandestine allotment Banks, Government Bonds and
strategies and so on., the present speculators accept accepted that balance barter is a
analytical babyhood of accepting speedier and college profits for their ventures if
assorted with the profits becoming in accepted adventure techniques

INTRODUCTION

India is a creating nation. These canicule abundant individuals are absorbed to

put assets into bread-and-butter markets decidedly on ethics to get cogent yields, and
to additional amount in fair manner. Ethics are bold a noteworthy job in charge of
designation to the firm the ancient starting point. Previous the giving of reward idea,
huge quantities of banking specialists are actualization at put assets into balance
exchange.

In an industry addled with atheism and a banking barter progressively harder

to apprehend and action with, on the off adventitious that one looks harder abundant
there may in any case be an accurate adviser for the Day Trader and Short Term
Investor.The amount of a aegis speaks to an accord. It is the amount at which one
alone consents to acquirement and addition consents to sell. The amount at which a
charlatan is blessed to acquirement or advertise depends basically on his desires. On
the off adventitious that he anticipates that the security's amount should rise, he will
get it; if the banking specialist anticipates that the amount should fall, he will
advertise it.
OBJECTIVES OF THE STUDY.

• Detailed assay of Pharmaceutical Sector which is outfitting appear accepted

measures

• Analyze the aftereffect of abstract factors on industry's and friends' affairs

• Comparative analysis of 5 executives in the firm which absorb Cipla, Dr Reddys,

GlaxoSmithKline, Lupin and Ranbaxy through capital examination.

NEED OF THE STUDY

The proprietors of the alignment charge to pay accepted artifice and arch amount
opposed the conclusion .

Raw material is cartel in an organization, with anniversary allocation of banal

speaking to a little bit of possession.

The added offers you claim, the a greater bulk of the alignment you possess. The
added offers you possess, the added profits you annex if the alignment makes a
benefit. In the money accompanying world, control is appointed "Value".

SCOPE OF THE STUDY

The adventure depends on instruments like key analysis and admeasurement

examination. Further, the assay depends on abstracts of a lot of contempo 5 years.

• The assay is fabricated by answer over 5 organizations for archetype Cipla, Dr

Reddys, GlaxoSmithKline, Lupin and Ranbaxy.

• The admeasurement of the analysis is belted to a period of 4 years.

• The amount is accountable to just the acute analysis of the best stocks.
 LIMITATIONS OF STUDY

This abstraction has been directed artlessly to appreciate Equity assay for banking
specialists.

• The abstraction is bound to three organizations abased on Fundamental

investigation.

• The abstraction is belted to the organizations accepting values.

• complete survey of the fleck was unrealistic because of accountable admeasurement

of the undertaking.

• There was a limitation as to time allocation for the analysis anticipate about for
archetype for a time

METHODOLOGY

• Research plan or analysis aesthetics is the alignment of gathering, analytic and advice
the advice to assay the affair and acknowledge to the accessible aperture in such a
way breadth the costs can be bound and the ideal amount of carefulness can be able to
blow abject at a specific end.

• The aesthetics activated in the analysis for the acme of the adventure and the
attainment of the assignment targets.

• The archetype of the stocks to accumulate abetting advice has been called based on
Random Sampling. The stocks are best in a candid way and anniversary banal is best
charge less of altered stocks picked. The stocks are browsed the biologic area.

• The archetype admeasurement for the abundance of stocks is taken as 5 for key assay
of stocks as above analysis is absolute and requires point by point anticipate about
REVIEW OF LITERATURE

EQUITY ANALYSIS

Investment success is appealing abundant a bulk of accurate alternative and

timing of banal purchases accompanying with absolute analogous to an individuals
accident tolerance. In acclimation to backpack out selection, timing and analogous
accomplishments an broker accept to conduct abysmal aegis analysis.

Investors acquirement disinterestedness shares with two basal objectives;

1. To accomplish basal profits by affairs shares at college prices.

2. To acquire allotment income.

These two factors are afflicted by a host of factors. An broker has to anxiously
accept and assay all these factors. There are essentially two ways to abstraction aegis
prices and appraisal i.e. axiological assay and abstruse analysis

The bulk of accepted banal is bent in ample admeasurement by the

achievement of the close that issued the stock. If the aggregation is advantageous and
can authenticate backbone and growth, the bulk of the banal will increase. If ethics
access again prices chase and allotment on an investment will increase. However, just
to accumulate the adeptness broker on their toes, the mix is complicated by the
accident factors involved. Axiological assay examines all the ambit of accident
acknowledgment and the probabilities of return, and merges them with broader bread-
and-butter assay and greater industry assay to codify the appraisal of a stock.

FUNDAMENTAL ANALYSIS
Key assay is a activity for anticipating the approaching bulk developments of a
bread-and-butter apparatus abased on monetary, political, ecological and added
important apparatus and insights that will access the axiological chargeless bazaar
activity of whatever underlies the money accompanying instrument. It is the analysis
of financial, industry and accompany altitude with an end ambition to adjudge the
admiration of an organization's stock.

10
 Above analysis commonly centers about key abstracts in organization's
account summaries to adjudge whether the banal bulk is finer esteemed. The
appellation basically alludes to the assay of the bread-and-butter abundance of a
money accompanying aspect instead of just its bulk developments. The basal study is
to appraise the ingrained adoration of a security. It need that cipher shall buy or
advertise an activity based on tips and $.25 of gossip.

The arch access calls aloft the banking specialists to achieve on his
acquirement or advertise best based on a nitty abrasive assay of the abstracts about
the organization, about the business, and the economy. It is contrarily alleged "top-
down methodology". This alignment endeavors to appraise the bread-and-butter
situation, industry position and the alignment desires and is contrarily alleged
"financial industry-organization access (EIC approach)".

Therefore the EIC access includes three stages:

1. Economic analysis

2. Industry analysis

3. Company analysis

11
 DATA ANALYSIS & INTERPRETATION

RATIO ANALYSIS OF CIPLA, DR REDDYS,

GLAXOSMITHKLINE, LUPIN AND RANBAXY

EARNINGS PER SHARE

EARNINGS PER SHARE

YEARS Mar „18 Mar „17 Mar „16 Mar „15 Mar‟14
CIPLA 20.26 8.59 9.02 9.99 13.47
DR REDDYS 27.53 70.09 28.26 33.29 50.11
GLAXOSMITHKLINE 59.28 64.40 63.48 68.07 60.48
LUPIN 45.52 37.60 54.02 50.35 72.96
RANBAXY 5.69 10.21 16.56 -24.85 13.61

Interpretations
EPS measures the benefit accessible to the value investors per share, that is, the sum
that they can jump on each offer held. CIPLA and DR Reddy's have been recording a
predictable development in the EPS in the course of the most recent five years.
GlaxoSmithKline has likewise enrolled a steady EPS of around 60% over the most
recent five years. Despite the fact that fluctuating, LUPIN has likewise conveyed
great EPS with the limit of Rs. 73 out of 2014. RANBAXY is the main odd player in
the gathering enrolling a negative EPS in 2013 however recuperated strongly in 202.

12
 SALES

SALES In Rs.Cr
Mar „18 Mar „17 Mar „16 Mar „15 Mar‟14
CIPLA 3,103.62 3,656.92 4,293.95 5,295.33 5,657.85
DR REDDYS 2,101.97 3,872.92 3,428.40 4,080.40 4,469.60
GLAXOSMITHKLINE 1,579.58 1,681.07 1,721.12 1,762.64 1,924.27
LUPIN 1,717.43 2,051.70 2,661.62 2,997.49 3,723.96
RANBAXY 3,727.05 4,218.98 4,344.39 4,676.21 4,797.49

Interpretations: All the five organizations have appeared positive pattern in deals
in the course of recent years. Despite the fact that lull in the economy brought
obstacles, social insurance organizations are the least affected and can possibly
develop in future as loads of items are still to include their portfolio. In addition
expanded interest in outside market additionally is by all accounts a positive sign for
better future.

13
 DIVIDEND PER SHARE

DIVIDEND PER SHARE

YEARS Mar „18 Mar „17 Mar „16 Mar „15 Mar‟14
CIPLA 2.00 2.00 2.00 2.00 2.00
DR REDDYS 5.00 3.75 3.75 6.25 11.25
GLAXOSMITHKLINE 31.00 36.00 40.00 30.00 31.00
LUPIN 6.50 5.00 10.00 12.50 13.50
RANBAXY 8.50 8.50 8.50 -- --

Interpretations:
CIPLA has proclaimed a steady profit of Rs.2 per share in the course of the most
recent five years. Dr Reddys has been enlisting a decent development over the most
recent two years. Glaxo Smith Kline had as well been predictable in announcing the
profits. Lupin has likewise been enlisting a decent development in pronouncing the
profits. Once more, RANBAXY is the main odd player without proclaiming any
profits

14
 RETURN ON INVESTMENT (ROI)

Return on Investment
YEARS Mar „18 Mar „17 Mar „16 Mar „15 Mar‟14
CIPLA 30.78 20.70 18.72 17.89 18.31
DR REDDYS 9.33 26.91 9.87 10.66 14.30
GLAXOSMITHKLINE 52.93 45.66 39.51 37.41 29.12
LUPIN 28.37 34 33.66 30.31 25.64
RANBAXY 8.92 16.19 24.34 -29.5 14.44

Interpretations
Return for money invested is a standout amongst the most significant proportions
utilized for estimating the general proficiency of a firm and decides if the interests in
the organizations are appealing or not. Glaxo Smith Kline has the best ROI of about
30% pursued by Lupin with 25.64%. Cipla, Ranbaxy and Dr Reddy's have a ROI of
18.31%, 14.44% and 14.30 separately.

15
FINDINGS

From the advice analysis and understandings of the accommodation of 5

organizations' viz. Cipla, DR Reddys, Lupin, Glaxosmithkline and Ranbaxy, the
accompanying discoveries accept been given:

• CIPLA and DR Reddy's accept been recording a reliable development in the EPS
throughout the a lot of contempo 5 years. GlaxoSmithKline has additionally enlisted a
abiding EPS of about 60% over the a lot of contempo 5 years. In animosity of the
actuality that fluctuating, LUPIN has additionally conveyed abundant EPS with the
absolute of Rs. 73 out of 2014. RANBAXY is the capital odd amateur in the
acquisition enrolling a abrogating EPS in 2011 about recuperated advisedly in 2014.

• All the 5 organizations accept appeared absolute arrangement in deals in the advance
of contempo years. In animosity of the actuality that abeyance in the abridgement
brought obstacles, alleviative casework organizations are the atomic afflicted and can
possibly advance in approaching as bunches of items are still to cover their portfolio.
In accession broadcast absorption in alfresco bazaar additionally is by all accounts a
absolute assurance for bigger future.

SUGGESTIONS
• Except for Ranbaxy, the assorted organizations arise to be a appropriate wagered for
venture.

• Glaxosmithkline with the a lot of acute Rate of Return is appropriate for

acquirement over the continued haul. The alignment additionally pays the greatest
accumulation assorted with its friends.

• Lupin pursues Glaxosmithkline apropos ROI and Dividend and it can additionally
be appropriate for a purchase.

• RANBAXY for assertive affidavit had been falling abaft in the chase and can be
dodged in the abbreviate run.

16
CONCLUSION

The standpoint for Indian pharma allotment for 2014 is steady. Assets and
gainfulness of Indian accepted based biologic organizations will accumulation by
proceeded with absorption for generics. Solid assets perceivability accumulated with
abiding alive gainfulness edges and belted capex spending would aftereffect in
abiding acclaim profiles for Fitch-evaluated substances. Be that as it may, clamminess
would abide a anguish for the allotment principally by advantage of top alive basic
necessities.

US bazaar is relied aloft to be the axiological development disciplinarian for

the absorption of generics. It is additionally advancing that that Indian biologic
organizations should see accumulation perceivability from the bounded markets and
the adorning affairs of re-appropriating. The accretion activity appear generics a
allotment of common trailblazer organizations to either set boutique in India or
appearance unions and associations with Indian biologic organizations will be added
assets triggers for the part.

During FY11, the edges of Indian biologic organizations will for the a lot of
allotment break abiding apprenticed by accretion calibration in the all-encompassing
portion. This is additionally accepted to advance into FY12. Fitch expects the
gainfulness of Indian biologic organizations to accumulate on profiting by bigger
geographic and annual blend, just as from college absolute acceptance levels. In
animosity of the positives that would administer bend extensions, animosity and
consistent amount disintegrations could arrest the accustomed improvement. Alive
basic levels for the analysis are apprenticed to break top and would in all anticipat ion
abnormally affect the clamminess profiles of littler biologic organizations. For bigger
and boilerplate admeasurement biologic organizations, size, calibration and
acceptability will empower them to accession annual and bigger accord with their
liquidity.

Drawback dangers to the angle could be by advantage of authoritative and

case dangers. Fitch takes agenda of that authoritative dangers beaming from superior
issues will decidedly affect the assets perceivability of Indian biologic organizations.

1
7
36
BIBILIOGRAPHY

Text Books

Security Analysis and Portfolio Management by Punithavathy Pandian, Vikas

Publications.

Security analysis and portfolio management by V.A. Avadhani

Financial Markets and Services by Gordon and Natarajan, Himalaya
Publications.
Financial Management by Shashi K Gupta and R. K Sharma, Kalyani
Publications.

Newspapers

Economic times
Business line

Websites

www.nseindia.com

www.bseindia.com
www.investopedia.com
www.moneycontrol.com
www.indiainfoline.com
www.sebi.gov.in
www.yahoofinance.com

CNBC TV18 – “The Informed Investor” supported by SEBI and presented by

NS

1
8
19